Universal Ibogaine Inc.

IBOGFOTCHealthcare● Active

$0.02

$-0.01(-40.45%)

Market Cap$5850454

P/E Ratio—

52W High$0.35

52W Low$0.0023

Avg Volume1.4M

Open$0.03

Beta4.37

Free Cash Flow Financials Revenue

Universal Ibogaine Inc. (IBOGF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IBOGF · free cash flow · updated Jun 15, 2026

Core FCF metrics

IBOGF · FCF · TTM · margin & CAGR

Free cash flow was −$4.4M for FY2022 (fiscal year ending 2022-07-31), down 36.3% year-over-year The FCF margin was -413.6%.

FY2022 Free Cash Flow−$4.4M▼ -36.3% YoY

Trailing 12M (TTM)−$1.2Mtrailing 4 quarters sum

FCF Margin-413.6%−$4.4M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IBOGF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$4.3M(0M)−$4.4M▼ 36.3%-413.6%

FY2021−$3.2M(0M)−$3.2M▼ 2531.1%—

FY2020−$121,985(0M)−$123,514▼ 71.6%—

FY2019−$71,993(0M)−$71,993▲ +77.5%—

FY2018−$320,341(0M)−$320,341——

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IBOGF · P/FCF · FCF yield · FCF per share

Universal Ibogaine Inc. (IBOGF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-07-31

Cash flow statement summary

IBOGF · cash flow statement · operating / investing / financing

For FY2022, Universal Ibogaine Inc. generated −$4.3M in operating cash flow and spent 0M in capital expenditures, yielding −$4.4M in free cash flow.

Operating Activities

−$4.3M

Cash from core business operations

2022-07-31

Investing Activities

−$2.1M

CapEx, acquisitions & investments

2022-07-31

Financing Activities

+$7.0M

Buybacks, dividends & debt

2022-07-31

FCF FormulaOperating CF (−$4.3M) − |CapEx| (0M) = FCF (−$4.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IBOGF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Universal Ibogaine Inc.YOU

IBOGF

−$4.4M-36.3%-413.6%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Universal Ibogaine Inc. (IBOGF) reported free cash flow of −$4.4M for FY2022 (fiscal year ending 2022-07-31), down 36.3% year-over-year. The FCF margin was -413.6%.

Universal Ibogaine Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 5 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IBOGF free cash flow · 8 questions

Universal Ibogaine Inc. free cash flow was −$4.4M for FY2022, down 36.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.2M.

IBOGF free cash flowIBOGF FCFIBOGF FCF 2022IBOGF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Universal Ibogaine Inc. · Universal Ibogaine Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026